Rallybio (RLYB) Net Income towards Common Stockholders (2023 - 2025)
Historic Net Income towards Common Stockholders for Rallybio (RLYB) over the last 3 years, with Q3 2025 value amounting to $16.0 million.
- Rallybio's Net Income towards Common Stockholders rose 24789.92% to $16.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.9 million, marking a year-over-year increase of 8006.85%. This contributed to the annual value of -$55.5 million for FY2024, which is 2342.29% up from last year.
- Latest data reveals that Rallybio reported Net Income towards Common Stockholders of $16.0 million as of Q3 2025, which was up 24789.92% from -$9.4 million recorded in Q2 2025.
- Rallybio's Net Income towards Common Stockholders' 5-year high stood at $16.0 million during Q3 2025, with a 5-year trough of -$19.6 million in Q4 2023.
- For the 3-year period, Rallybio's Net Income towards Common Stockholders averaged around -$11.8 million, with its median value being -$15.7 million (2024).
- Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first crashed by 948.37% in 2024, then surged by 24789.92% in 2025.
- Rallybio's Net Income towards Common Stockholders (Quarter) stood at -$19.6 million in 2023, then skyrocketed by 45.93% to -$10.6 million in 2024, then surged by 250.9% to $16.0 million in 2025.
- Its last three reported values are $16.0 million in Q3 2025, -$9.4 million for Q2 2025, and -$8.9 million during Q1 2025.